Goldman upgrades Rocket Pharmaceuticals to Neutral
Alpha Vantage · ad-hoc-news.de · · AI-summarised by FinFlash
Goldman Sachs raised its price target on Rocket Pharmaceuticals to USD 4.00 from USD 3.00 and upgraded the stock to Neutral from Sell. The new target remains well below the USD 7.77 consensus of twelve analysts. The loss-making biotech traded at EUR 2.10 with a USD 259.1 million market capitalization.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.